Ann: In-licencing of Phase II-ready molecule - presentation-NRT.AX, page-19

Its good and it fills a gap nicely in the schedule and we are now in-clinic, and around the corner from Phase 2 trials with this new addition.

When Cantrixil enters in the next month or so we have two drugs in trials one in phase 1 and one about to go to phase 2.... and with IND + one starting late next year.

They have molecule for phase 2 trials and after phase two we enter into partnership on phase three trials with a big brother it seems a good decision - we could be in funded phase 3 with 'something' within two years.

It also opens the doors for Cantrixil looking for a partner for phase three which must still be a good two years of.

It shortens the time to potential revenue.

If so it proves Novogen can now handle a relationship and the progression to revenue streams - meaning self funded... its a new Novogen.

I like it though haven't read through properly.